These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer. Shim SH; Lee JY; Lee YY; Park JY; Lee YJ; Kim SI; Han GH; Yang EJ; Noh JJ; Yim GW; Son JH; Kim NK; Kim TH; Kong TW; Choi YJ; Cho A; Lim H; Jang EB; Cho HW; Suh DH J Gynecol Oncol; 2024 Mar; 35(2):e66. PubMed ID: 38330382 [TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Husseinzadeh N; Husseinzadeh HD Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063 [TBL] [Abstract][Full Text] [Related]
4. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers. Wolford JE; Ferrigni E; Margul D; Herzog TJ Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591 [TBL] [Abstract][Full Text] [Related]
5. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies. Eskander RN Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335 [TBL] [Abstract][Full Text] [Related]
7. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers. Muggia FM Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530 [TBL] [Abstract][Full Text] [Related]
11. The evolving landscape of antibody-drug conjugates in gynecologic cancers. Tolcher A; Hamilton E; Coleman RL Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Efficacy and Adverse Events After Second Immunotherapy Exposure in Endometrial and Cervical Carcinoma. Morton M; Marcu I; Levine M; Cosgrove C; Backes F; O'Malley D; Chambers L Obstet Gynecol; 2023 Aug; 142(2):360-363. PubMed ID: 37411031 [TBL] [Abstract][Full Text] [Related]
14. Immuno-oncology for Gynecologic Malignancies. How J; Patel A; Jazaeri A Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014 [TBL] [Abstract][Full Text] [Related]
15. Major clinical research advances in gynecologic cancer in 2015. Suh DH; Kim M; Kim HJ; Lee KH; Kim JW J Gynecol Oncol; 2016 Nov; 27(6):e53. PubMed ID: 27775259 [TBL] [Abstract][Full Text] [Related]
16. Updates in the Use of Targeted Therapies for Gynecologic Cancers. Cantillo E; Blanc-Durand F; Leary A; Slomovitz BM; Fuh K; Washington C Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438582. PubMed ID: 38788185 [TBL] [Abstract][Full Text] [Related]
17. Genomic-Based Therapy of Gynecologic Malignancies. Markman M Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436 [TBL] [Abstract][Full Text] [Related]
18. [Minimally invasive treatment of gynecologic cancers]. Ichikawa Y; Yoshikawa H Gan To Kagaku Ryoho; 2001 Aug; 28(8):1090-3. PubMed ID: 11525023 [TBL] [Abstract][Full Text] [Related]
19. Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies. Markman M Womens Health (Lond); 2016 Jul; 12(4):396-9. PubMed ID: 27638892 [TBL] [Abstract][Full Text] [Related]
20. Integrating antibody drug conjugates in the management of gynecologic cancers. Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]